scholarly journals Cell-free DNA in Human Follicular Fluid as Biomarker for Intracytoplasmic Sperm Injection Procedure Outcome

2021 ◽  
Vol 9 (B) ◽  
pp. 1745-1750
Author(s):  
Maanee Azzam ◽  
Adeela Hamood ◽  
Hind Abdulkadim
Keyword(s):  
Pregnancy Outcome ◽  
Follicular Fluid ◽  
Fertilization Rate ◽  
P Value ◽  
Human Follicular Fluid ◽  
Cell Free Dna ◽  
Free Dna ◽  
Detection Approach ◽  
Iraqi Women ◽  
High Level

Background: Follicular fluid considered as an important microenvironment for oocyte development, cell free-DNA (cfDNA) fragments that are found in this fluid and are released from cell apoptosis and/or necrosis, aimed to quantified the level of cf-DNA, in the follicular fluid and to assess any relation between the level of cf-DNA in this fluid with women’s age, duration of infertility, cause of infertility, her ovarian reserve values. Methods: Eighty-nine women were prospectively included in this study FF cf-DNA which was determined by conventional real time PCR-syber green detection approach which quantified by ALU-specific primers. Results: cell-free DNA (cfDNA) level in Follicular fluid samples of Iraqi women level was; cfDNA (Mean±SD, 0.916±0.106 ng/μl). there was no significant relation between cfDNA and pregnancy outcome, but very low level and very high level cf DNA were related to negative pregnancy outcome, cfDNA was second most important predictive factor of pregnancy outcome after fertilization rate, but both not statistically significant p value was (0.622 and 0.241) respectively. Conclusion: current study notice that cfDNA in the follicular fluid may mainly reflect the cellular activity and the balance between programed apoptosis and cell necrosis.

scholarly journals Cell-free DNA in human follicular fluid as a biomarker of embryo quality

2014 ◽  
Vol 29 (12) ◽  
pp. 2661-2669 ◽  
Author(s):  
E. Scalici ◽  
S. Traver ◽  
N. Molinari ◽  
T. Mullet ◽  
M. Monforte ◽  
...  
Keyword(s):  
Follicular Fluid ◽  
Embryo Quality ◽  
Human Follicular Fluid ◽  
Cell Free Dna ◽  
Free Dna

Cell-free DNA in human follicular fluid as new non-invasive biomarker of embyo quality

2014 ◽  
Vol 102 (3) ◽  
pp. e62
Author(s):  
E. Scalici ◽  
S. Traver ◽  
T. Mullet ◽  
A. Ferrières ◽  
M. Monforte ◽  
...  
Keyword(s):  
Follicular Fluid ◽  
Human Follicular Fluid ◽  
Cell Free Dna ◽  
Non Invasive ◽  
Free Dna

Assessing the impact of clonal hematopoiesis in disease monitoring using targeted cell-free DNA (cfDNA) sequencing technology.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14530-e14530
Author(s):  
Stephanie J. Yaung ◽  
Liu Xi ◽  
Corinna Woestmann ◽  
Christine Ju ◽  
Daniel M. Klass ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Mononuclear Cells ◽  
Response To Therapy ◽  
Targeted Sequencing ◽  
P Value ◽  
Disease Monitoring ◽  
Cell Free Dna ◽  
Clonal Hematopoiesis ◽  
Free Dna ◽  
The Impact

e14530 Background: Somatic variants found in plasma cell-free DNA (cfDNA) may derive from either solid tumors or clonal hematopoiesis (CH). Little is known about how this may impact plasma-based longitudinal disease monitoring using targeted sequencing of circulating tumor DNA (ctDNA). Methods: To assess the potential impact of CH in disease monitoring, we evaluated monitoring algorithms by targeted sequencing with and without matched peripheral blood mononuclear cells (PBMC). Samples were collected from a prospective observational study, where 62 late stage lung adenocarcinoma subjects were treated with first-line chemo or chemoradiation therapy. Pre-treatment plasma cfDNA and matched PBMC were analyzed with the AVENIO ctDNA Surveillance Kit (For Research Use Only, not for use in diagnostic procedures), a sequencing panel of 198 kilobases targeting cancer genes. Median input amounts of 25 ng cfDNA and 50 ng PBMC DNA were sequenced to median deduplicated depths of 4582 and 6134, respectively. Results: A median of 120 single nucleotide variants were detected per cfDNA sample, with 93.1% of these identified in matched PBMC. Most PBMC-matched cfDNA variants were germline SNPs, with allele frequency (AF) ~ 50% or 100%. A median of 1 (range 0-5) PBMC-matched cfDNA variants per sample were detected with an AF < 10%, consistent with CH. The number of these variants was positively associated with age (p-value = 0.0039) and the most frequently mutated gene was TP53. The remaining somatic variants (i.e., in cfDNA and not PBMC) had an AF range 0.03-40.9%. These PBMC-informed variants (median of 7 per sample) were used in longitudinal monitoring in the first post-treatment plasma sample to assess early response to therapy. Association between ctDNA level and progression-free survival using the same monitoring algorithm yielded nearly identical results on somatic variants derived from filtering approaches independent of matched PBMC (HR 0.32; 95% CI 0.16 - 0.65; log-rank P = 0.0009) and the PBMC-informed method (HR 0.31; 95% CI 0.14 - 0.66; log-rank P = 0.0013). Conclusions: A targeted panel focused on solid tumors by design has limited impact from CH. For disease monitoring applications in a non-MRD setting, measuring multiple variants instead of a single variant further enables robust classifiers that can moderate the impact of variants, if any, from CH.

scholarly journals Association between low fetal fraction in cell‐free DNA testing and adverse pregnancy outcome: A systematic review

2021 ◽  
Author(s):  
Peter G. Scheffer ◽  
Soetinah A.M. Wirjosoekarto ◽  
Ellis C. Becking ◽  
Marjan M. Weiss ◽  
Caroline J. Bax ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pregnancy Outcome ◽  
Adverse Pregnancy Outcome ◽  
Dna Testing ◽  
Cell Free Dna ◽  
Free Dna ◽  
Adverse Pregnancy ◽  
Fetal Fraction

scholarly journals A Pilot Prospective Study of Plasma Cell free DNA Whole Genome Sequencing Identified Chromosome 7p Copy Number Gains is a Specific Biomarker for Early Lung Cancer detection

2020 ◽  
Author(s):  
Hongjie Yu ◽  
Xiaojun Yu ◽  
Jia Tang ◽  
Xun Lu ◽  
Haitao Ma
Keyword(s):  
Lung Cancer ◽  
Plasma Cell ◽  
Cancer Detection ◽  
Copy Number ◽  
Chromosome 7 ◽  
P Value ◽  
Tumor Biomarker ◽  
Cell Free Dna ◽  
Free Dna ◽  
Lung Cancer Detection

Abstract purpose: Chromosome 7 is playing an important role in lung tumorigenesis. Here we investigate whether chromosome 7p copy number gain as a detectable genetic events with plasma cell free DNA for early lung cancer detection biomarker. Methods: Eighteen surgical eligible lung cancer patients and eighteen non-cancer controls were recruited. Peripheral blood was collected before surgery. Cell free DNA was profiled with low coverage whole genome sequencing. Chromosome 7 copy number gains were defined as chr7 normalized coverage≥1.0005 and P value<0.05. Plasma cell-free DNA chr7 copy gains were then compared to pathological examinations on surgical tissues.Results: 83.3% patients were confirmed as malignancy post-operation, with 12 adenocarcinoma and 3 squamous-carcinoma. The other 16.7% were benign lesions. Cell free DNA was successfully extracted from pre-surgical plasma samples, with concentration range from 0.18 to 0.49 ng/ul. Chromosome 7 short arm copy gains were found in 66.7% (10/15) patients, including 66.7% (4/6) T1aN0M0 and 50.0% (1/2) Tis patients, otherwise, chr7p gain was found in 0% (0/3) benign lesions. The specificity was further examined in 18 volunteers who undergoing routine body examinations. Meanwhile, positive CEA and CYFRA21-1 was only found in 1/18 (5.7%) and 4/18 (22.2%). Taking together, UCAD chr7p or UCAD chr7p and tumor biomarker positivity can predict 12/15(80%, 95% CI:49.0-94.3%) early lung cancers. Further analyses showed that chr7p copy number gains tends to be enriched in EGFR/KRAS silent patients (fisher. test, P value=0.077). Conclusions: Chromosome 7p copy gains might be a useful peripheral blood tumor biomarker from lung cancer detection.

scholarly journals Cell‐free DNA content in follicular fluid: A marker for the developmental ability of porcine oocytes

2019 ◽  
Vol 19 (1) ◽  
pp. 95-103 ◽  
Author(s):  
Kana Ichikawa ◽  
Hidenori Shibahara ◽  
Komei Shirasuna ◽  
Takehito Kuwayama ◽  
Hisataka Iwata
Keyword(s):  
Follicular Fluid ◽  
Dna Content ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals High concentration of plasma cell free DNA alerting disease recurrence in high risk neuroblastoma children

2019 ◽  
Author(s):  
Yan Su ◽  
Lijun Wang ◽  
Chiyi Jiang ◽  
Zhixia Yue ◽  
Hongjun Fan ◽  
...  
Keyword(s):  
High Risk ◽  
Plasma Cell ◽  
Maintenance Treatment ◽  
Treatment Phase ◽  
Disease Recurrence ◽  
High Rate ◽  
High Concentration ◽  
Cell Free Dna ◽  
Free Dna ◽  
High Level

Abstract Background Neuroblastoma is the third-most common cancer in children. The high rate of tumor recurrence accounts for a low survival rate in high risk neuroblastoma. Therefore it is clinically of extreme importance to find an effective biomarker for alerting disease recurrence.Methods Total 116 high risk neuroblastoma patients were recruited in Beijing Children’s Hospital from February, 2015 to December, 2017. All patients had received multiple-disciplinary treatment, then went into maintenance treatment phase after evaluation. Blood samples were collected to quantify plasma cell-free DNA (cfDNA) at time points of the beginning of maintenance treatment, every three months afterwards, and diagnosis of recurrence.Results Results showed that 36 high risk neuroblastoma patients developed recurrence during maintenance treatment. The plasma cfDNA concentration was significantly higher in recurrence than in event-free patients (29.34 ng/ml VS 10.32 ng/ml). The time span of cfDNA level higher than 29 ng/ml was consistently detected ahead of recurrence at mean of 0.55 months. The ROC analysis showed that AUC was 0.825, optimal sensitivity and specificity of 80.6% and 71.3% respectively, at cfDNA level of 12.93 ng/ml.Conclusions We concluded that high level of plasma cfDNA could serve as a promising molecular marker to alert recurrence disease in high risk neuroblastoma children.

Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 11005-11005
Author(s):  
Alberto Bardelli ◽  
Simona Corso ◽  
Andrea Bertotti ◽  
Sebastijan Hobor ◽  
Giulia Siravegna ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Acquired Resistance ◽  
Genetic Alterations ◽  
Kras Mutations ◽  
Cell Free Dna ◽  
Free Dna ◽  
Met Amplification ◽  
High Level ◽  
Tumor Biopsies ◽  
Egfr Antibody

11005 Background: The anti EGFR monoclonal antibodies cetuximab and panitumumab are used to treat metastatic colorectal cancer patients but their clinical efficacy is limited by the development of acquired resistance. We recently reported that secondary KRAS mutations are responsible for acquired resistance in approximately 50% of the patients who initially respond to cetuximab or panitumumab (Misale et al., Nature 2012; Diaz et al., Nature 2012). Here we studied the molecular bases of relapse in CRC patients who do not develop KRAS mutations during the course of anti-EGFR therapy. Methods: Next generation sequencing was applied to tumor biopsies to identify genetic alterations associated with relapse to cetuximab and panitumumab in mCRC patients. Detection and quantitation of genetic alterations in circulating tumor DNA was used to monitor the occurrence of KRAS mutations and MET amplification in blood samples. Results: Molecular analyses of tumor biopsies from patients who did not develop KRAS mutations during anti-EGFR therapy revealed high level of amplification of the MET proto-oncogene in 3/5 cases. Quantitative PCR, FISH and IHC analysis confirmed high level of MET amplification in the post-therapy samples but not in the matched pre-treatment tissues. We developed a PCR based assay to detect the presence of the MET amplicon in circulating, cell-free, DNA. We found that MET amplification could be detected in the blood as early as 3 months after initiation of anti EGFR therapy. To functionally evaluate the role of MET amplification on resistance to anti EGFR antibody therapies we exploited patient-derived CRC xenografts (‘xenopatients). We found that (2/2) xenopatients established from MET amplified tumors were completely refractory to cetuximab but showed sensitivity to the Met inhibitor crizotinib. Conclusions: Amplification of the MET proto-oncogene is responsible for acquired acquired resistance to anti-EGFR antibody therapy in a subset of CRCs. The emergence of MET amplification in circulating, cell-free, DNA may be used to select patients most likely to benefit from anti MET therapies.

Sign in / Sign up

Export Citation Format

Share Document